VivoSeq
Oncology

Salivary Gland Cancer

49

Pipeline Programs↗

4

Active Trials↗

25

Companies Involved↗

Salivary Gland Cancer is a moderately active landscape with 49 programs across 25 companies. The most active players are Poseida Therapeutics, Inc., Merck & Co., Bellicum Pharmaceuticals. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

80/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Poseida Therapeutics, Inc.

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1B

Bellicum Pharmaceuticals

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 2Novartis logo

Novartis

3 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

40 of 51 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody816%Protein / enzyme12%Cell therapy12%Radiopharmaceutical12%

Small molecule leads; the ring shows all 51 classified programs, each share of the total. Modality classified for 100% of 51 pipeline programs.

Analysis

Trial Status

28

clinical trials

Completed16 · 57%
Unknown status4 · 14%
Terminated4 · 14%
Active, not recruiting2 · 7%
Recruiting1 · 4%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

28 trials

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Recruiting·—·Phase 2·NCT06805617·35 enrolled
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Active, not recruiting·MMayo Clinic·Phase 2·NCT04895735·45 enrolled
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT05669664·21 enrolled
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
Not yet recruiting·—·Phase 2·NCT07464366·68 enrolled
Activity of Sorafenib in Salivary Gland Cancer
Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01703455·37 enrolled
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
Completed·—·Phase 2·NCT00004163·14 enrolled
Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14
Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02857712·26 enrolled
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
Completed·UUniversity Health Network, Toronto·N/A·NCT02069730·114 enrolled
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
Completed·UUniversity Health Network, Toronto·Phase 2·NCT00045669·16 enrolled
Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Completed·National Cancer Institute (NCI)·Phase 2·NCT00095563·40 enrolled
Iressa Study in Patients With Salivary Gland Cancer
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00509002·37 enrolled
Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers
Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02867852·24 enrolled
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03172624·64 enrolled
Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00002632·32 enrolled
Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery
Completed·—·Phase 2·NCT00003744·16 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)